GYRE Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

3 Analyst Rating

Wall Street analysts forecast GYRE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GYRE is 18.00 USD with a low forecast of 16.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

0 Hold

0 Sell

Strong Buy

Current: 7.790

Low

16.00

Averages

18.00

High

20.00

Current: 7.790

Low

16.00

Averages

18.00

High

20.00

H.C. Wainwright

initiated

$18

2025-08-26

Reason

H.C. Wainwright

Price Target

$18

2025-08-26

initiated

Reason

H.C. Wainwright initiated coverage of Gyre Therapeutics with a Buy rating and $18 price target. The company's lead asset hydronidone is a structural analog of the anti-fibrotic drug pirfenidone and a "potent inhibitor" of fibrosis, the analyst tells investors in a research note. The firm believes Gyre is "still flying under the radar with investors" despite a "compelling" portfolio of established therapeutics.

Valuation Metrics

The current forward P/E ratio for Gyre Therapeutics Inc (GYRE.O) is 35.77, compared to its 5-year average forward P/E of 11.43. For a more detailed relative valuation and DCF analysis to assess Gyre Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

11.43

Current PE

35.77

Overvalued PE

33.37

Undervalued PE

-10.51

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

8.65

Current EV/EBITDA

39.16

Overvalued EV/EBITDA

26.38

Undervalued EV/EBITDA

-9.08

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

1.35

Current PS

4.71

Overvalued PS

3.69

Undervalued PS

-0.98

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

GYRE News & Events

Events Timeline

No data

News

9.5

11-07NASDAQ.COM

GYRE THERAPEUTICS, INC. Reports Increase in Q3 Earnings

6.0

10-17NASDAQ.COM

Fresh Strong Sell Stocks for October 17th

9.0

08-26Benzinga

Gyre Therapeutics Emerges as a Notable Player in Liver Fibrosis Drug Development

People Also Watch

Frequently Asked Questions

What is Gyre Therapeutics Inc (GYRE) stock price today?

The current price of GYRE is 7.79 USD — it has increased 1.3 % in the last trading day.

What is Gyre Therapeutics Inc (GYRE)'s business?

Gyre Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of F351 (Hydronidone) for the treatment of MASH-associated fibrosis in the United States. It is also advancing a diverse pipeline in the PRC through its indirect controlling interest in Gyre Pharmaceuticals, including ETUARY therapeutic expansions, F573, F528, and F230. F351 is a structural derivative of ETUARY. F573 is its clinical-stage product candidate for the treatment of acute/acute-on-chronic liver failure (ALF/ACLF) in Phase 2 clinical trials in the PRC. F528 is a preclinical-stage candidate targeting chronic obstructive pulmonary disease. F230 is a clinical-stage compound for the treatment of pulmonary arterial hypertension. It is focused on commercializing therapies for the treatment of pulmonary fibrosis through its two therapeutic products: ETUARY (pirfenidone) and nintedanib. It is also focused on commercializing the avatrombopag product.

What is the price predicton of GYRE Stock?

What is Gyre Therapeutics Inc (GYRE)'s revenue for the last quarter?

Gyre Therapeutics Inc revenue for the last quarter amounts to 30.56M USD, increased 19.92 % YoY.

What is Gyre Therapeutics Inc (GYRE)'s earnings per share (EPS) for the last quarter?

Gyre Therapeutics Inc. EPS for the last quarter amounts to 0.03 USD, increased 200.00 % YoY.

What changes have occurred in the market's expectations for Gyre Therapeutics Inc (GYRE)'s fundamentals?

The market is revising Downward the revenue expectations for Gyre Therapeutics, Inc. (GYRE) for FY2025, with the revenue forecasts being adjusted by -3.18% over the past three months. During the same period, the stock price has changed by -1.39%.

How many employees does Gyre Therapeutics Inc (GYRE). have?

Gyre Therapeutics Inc (GYRE) has 574 emplpoyees as of December 15 2025.

What is Gyre Therapeutics Inc (GYRE) market cap?

Today GYRE has the market capitalization of 698.95M USD.